CTIS2024-511493-67-00RecruitingPhase 1
A first-in-human, phase I, single-center, open-label, dose-escalation trial in healthy volunteers to assess safety, tolerability, and immunogenicity of PANHPVAX, a vaccine targeting human papilloma L2 antigen formulated with cyclic di-AMP
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts0 sites45 target enrollmentStarted: May 28, 2024Last updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Enrollment
- 45
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 64 (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Not yet recruiting
Phase 1
A study to test different doses of BI 764532 in patients with small cell lung cancer and other neuroendocrine tumours that are positive for DLL3.Small cell lung carcinoma and neuroendocrine carcinomaJPRN-jRCT2080225308Boehringer Ingelheim19
Not yet recruiting
Phase 1
This trial is a phase 1, single-centre, open label, single-dose study of 89Zr-APOMAB using PET/CT imaging in a series of 18 participants who are known to have inoperable stage III or stage IV non-small cell lung cancer (NSCLC), or limited or extensive stage small cell lung cancer (SCLC), or FIGO stage IV grade 3 serous papillary Ovarian Cancer.Advanced Lung CancerAdvanced Ovarian CancerCancer - Lung - Non small cellCancer - Ovarian and primary peritonealCancer - Lung - Small cellACTRN12620000622909Central Adelaide Local Health Network18
Recruiting
Not Applicable
A Phase I, first-in-human, multicenter, open-label, dose escalation followed by an expansion phase clinical study of KBA1412 given as monotherapy or in combination with pembrolizumab in adults with advanced solid malignant tumorsmelanomaSolid Tumors10018865NL-OMON53468Kling Biotherapeutics B.V.22
Completed
Not Applicable
A phase 1, first-in-human, multicenter, open-label, dose-escalation study to characterize the safety and tolerability of MP0317 in patients with relapsed/refractory advanced solid tumorsNL-OMON51895Molecular Partners AG30
Not yet recruiting
Phase 1
A First-in-Human Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple MyelomaRelapsed Multiple MyelomaRefractory Multiple MyelomaCancer - MyelomaACTRN12622000856718Ichnos Sciences SA121